Objectives: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), to recommend optimal image acquisition and analysis methods to enable WB-MRI as an endpoint in NF clinical trials.Methods: A systematic process was used to review all published data about WB-MRI in NF syndromes to assess diagnostic accuracy, feasibility and reproducibility, and data about specific techniques for assessment of tumor burden, characterization of neoplasms, and response to therapy.Results: WB-MRI at 1.5T or 3.0T is feasible for image acquisition. Short tau inversion recovery (STIR) sequence is used in all investigations to date, suggesting consensus about the utility of this sequence for detection of WB tumor burden in people with NF. There are insufficient data to support a consensus statement about the optimal imaging planes (axial vs coronal) or 2D vs 3D approaches. Functional imaging, although used in some NF studies, has not been systematically applied or evaluated. There are no comparative studies between regional vs WB-MRI or evaluations of WB-MRI reproducibility.Conclusions: WB-MRI is feasible for identifying tumors using both 1.5T and 3.0T systems. The STIR sequence is a core sequence. Additional investigation is needed to define the optimal approach for volumetric analysis, the reproducibility of WB-MRI in NF, and the diagnostic performance of WB-MRI vs regional MRI. Neurology ® 2016;87 (Suppl 1):S31-S39 GLOSSARY ADC 5 apparent diffusion coefficient; DWI 5 diffusion-weighted imaging; FDG 5 fluorodeoxyglucose; MPR 5 multiplanar reformation; NF1 5 neurofibromatosis type 1; NF2 5 neurofibromatosis type 2; PNST 5 peripheral nerve sheath tumors; REiNS 5 Response Evaluation in Neurofibromatosis and Schwannomatosis; SNR 5 signal to noise ratio; STIR 5 short tau inversion recovery; SWN 5 schwannomatosis; WB-MRI 5 whole-body MRI.Whole-body MRI (WB-MRI) allows imaging of a large volume of the body in a single image acquisition session. It has been extensively investigated for the detection and staging of visceral and osseous tumors [1][2][3][4][5][6] and is well-suited to tumor syndromes including neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), 7-9 as these patients often have a high burden of tumors as well as large tumors that cross anatomic planes (figure). WB-MRI has been used to evaluate tumor burden and to characterize neoplasms in patients with NF syndromes [10][11][12][13][14][15][16][17][18][19][20][21][22][23] and is being used in some clinical trials to evaluate response to therapy (NCT01207687). A uniform image acquisition protocol and interpretation method would enable WB-MRI to be used as a key endpoint to assess tumor treatment response in multicenter clinical trials for NF-associated perip...